maraviroc

Ligand id: 806

Name: maraviroc

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 63.05
Molecular weight 513.33
XLogP 7.43
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Maraviroc is approved for use in combination antiretroviral treatment of patients infected with CCR5-tropic HIV-1 virus.

Maraviroc-induced CCR5 blockade was investigated for action in treating rheumatoid arthritis, but with discouraging clinical trial results. Other CCR5 antagonists (AZD5672 and ancriviroc) have also proven ineffective in RA clinical trials [5]
Mechanism Of Action and Pharmacodynamic Effects
CCR5 is a co-receptor for HIV-1 and other viruses, allowing these viruses to enter cells. Maraviroc selectively antagonises the interaction between the human CCR5 receptor and HIV-1 envelope glycoprotein gp120. This prevents the CCR5-tropic HIV-1 from entering the cells [2]. Maraviroc has also been shown to inhibit leukocyte trafficking and mucosal inflammation in a mouse colitis model [3], suggesting a CCR5-based interventional strategy with therapeutic potential in inflammatory bowel diseases.
External links